Roivant Sciences logged a -0.4% change during today's afternoon session, and is now trading at a price of $11.32 per share.
Roivant Sciences returned gains of 42.3% last year, with its stock price reaching a high of $13.24 and a low of $6.58. Over the same period, the stock outperformed the S&P 500 index by 17.7%. More recently, the company's 50-day average price was $9.58. Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. Based in London, United Kingdom, the mid-cap Health Care company has 904 full time employees. Roivant Sciences has not offered a regular dividend during the last year.
Growing Revenues With Increasing Reinvestment in the Business:
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Revenue (k) | $23,795 | $55,286 | $61,280 |
| Revenue Growth | n/a | 132.34% | 10.84% |
| Operating Margins | -3776% | -1671% | -1834% |
| Net Margins | -382% | -143% | -174% |
| Net Income (k) | -$90,999 | -$78,854 | -$106,433 |
| Net Interest Expense (k) | $2,809 | $7,041 | $15,808 |
| Free Cash Flow (k) | -$557,944 | -$695,165 | -$856,083 |
| Capital Expenditures | $5,806 | $17,436 | $12,690 |
| Current Ratio | 14.23 | 6.74 | 5.84 |
| Total Debt (k) | $360,555 | $539,980 | $411,467 |
Roivant Sciences does not have a meaningful trailing P/E ratio since its earnings per share are negative. Its forward EPS guidance is negative too, at $-1.15. The average P/E ratio for the Health Care sector is 30.21. Furthermore, Roivant Sciences is likely overvalued compared to the book value of its equity, since its P/B ratio of 9.56 is higher than the sector average of 4.08.
Roivant Sciences Has an Average Rating of Buy:
The 10 analysts following Roivant Sciences have set target prices ranging from $11.0 to $23.0 per share, for an average of $15.5 with a buy rating. As of April 2023, the company is trading -38.2% away from its average target price, indicating that there is an analyst consensus of strong upside potential.
Roivant Sciences has an average amount of shares sold short because 6.7% of the company's shares are sold short. Institutions own 67.9% of the company's shares, and the insider ownership rate stands at 30.26%, suggesting a large amount of insider shareholders. The largest shareholder is QVT Financial LP, whose 14% stake in the company is worth $1,273,970,153.
